Bristol-Myers Squibb to acquire Celgene in $74bn deal
03-01-2019
360b / Shutterstock.com
Pharmaceutical company Bristol-Myers Squibb (BMS) has acquired Cormorant Pharmaceuticals in a deal valued at up to $95 million.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Bristol-Myers Squibb, Cormorant, IL-8
